Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Subscribe To Our Newsletter & Stay Updated
